IPCALAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | IPCALAB | Market Cap | 38,840 Cr. | Current Price | 1,531 ₹ | High / Low | 1,624 ₹ |
| Stock P/E | 38.7 | Book Value | 292 ₹ | Dividend Yield | 0.26 % | ROCE | 17.3 % |
| ROE | 12.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,499 ₹ | DMA 200 | 1,450 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.14 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 56.1 | MACD | 8.64 | Volume | 3,67,675 | Avg Vol 1Wk | 2,14,309 |
| Low price | 1,252 ₹ | High price | 1,624 ₹ | PEG Ratio | -30.2 | Debt to equity | 0.11 |
| 52w Index | 75.0 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 30.1 |
Financials: Ipca Laboratories shows decent fundamentals with ROCE at 17.3% and ROE at 12.4%. EPS of ₹31.7 supports profitability, while quarterly PAT of ₹303 Cr. remains stable compared to ₹305 Cr. Debt-to-equity ratio of 0.11 indicates low leverage.
Valuation: P/E of 38.7 is higher than industry average (30.1), suggesting overvaluation. PEG ratio of -30.2 highlights weak growth-adjusted valuation. Dividend yield of 0.26% is modest.
Business Model: Ipca operates in the pharmaceutical sector with strengths in formulations and APIs. Competitive advantage lies in diversified product portfolio and export presence.
Entry Zone: Reasonable entry between ₹1,480–₹1,520 near DMA 50 (₹1,499). Long-term holding requires monitoring valuation compression and earnings growth.
Positive
- Strong book value of ₹292 supports intrinsic strength
- Low debt-to-equity ratio (0.11) ensures financial stability
- EPS of ₹31.7 reflects consistent profitability
- Stable PAT performance quarter-on-quarter
Limitation
- High P/E (38.7) compared to industry average (30.1) indicates premium valuation
- Negative PEG ratio (-30.2) signals weak growth outlook
- Dividend yield of 0.26% offers limited income appeal
- ROE (12.4%) is modest relative to peers
Company Negative News
- Valuation concerns due to stretched P/E and poor PEG ratio
- Weak growth-adjusted metrics may deter investors
Company Positive News
- Stable quarterly PAT (₹303 Cr. vs ₹305 Cr.) shows resilience
- Institutional holdings slightly increased (FII +0.01%, DII +0.14%)
Industry
- Pharma sector outlook remains positive with global demand
- Industry P/E at 30.1 highlights Ipca trading at premium valuation
Conclusion
Ipca Laboratories offers stable fundamentals with low debt and consistent earnings, but stretched valuations and weak growth-adjusted metrics limit upside. Entry around ₹1,480–₹1,520 is reasonable for cautious investors, though long-term holding requires monitoring of earnings growth and valuation normalization.
Would you like me to also prepare a peer benchmarking overlay comparing Ipca with Sun Pharma, Cipla, and Dr. Reddy’s, so you can evaluate relative valuation and efficiency in a modular HTML format?